ACTRN12610000684022已完成1 期
Combination Gefitinib and Methotrexate to Medically Treat Ectopic Pregnancies: A Phase I Clinical Toxicity Trial.
Dr Stephen Tong0 个研究点目标入组 12 人开始时间: 2010年8月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- Female
入选标准
- •Women diagnosed with stable ectopic pregnancy, with an hCG of less than 3000 IU/L and an ultrasound showing a gestational sac of under 3 cms.
排除标准
- •Haemodynamic instability, women of Japanese ethnicity, chronic lung problems/lung cancer history, severe dermatological and gastrointestinal disease history, liver or renal dysfunction, allergy to gefitinib/methotrexate.
研究者
相似试验
招募中
2 期
Combination Gefitinib and Methotrexate to Medically Treat Ectopic Pregnancies: A Phase II Study of EfficacyACTRN12611001056987Associate Professor Stephen Tong40
终止
1 期
Combination Gefitinib and Methotrexate for the Treatment of Persistent Gestational Trophoblastic Disease: A Phase I Clinical TrialACTRN12611000104954Miss Orla McNally, Director Gynaecological Oncology & Dysplasia12
进行中（未招募）
1 期
GEM study for ectopic pregnancyEUCTR2011-001747-69-GBMonash University30
尚未招募
3 期
Comparison of effectiveness and tolerance of Single drug Methotrexate or Combination of drugs i.e. Methotrexate and Gefitinib drug in patients with very advanced head and neck cancerCTRI/2021/04/032577JIPMER
已完成
不适用
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.non-small cell lung cancerJPRN-UMIN000000637Juntendo University, School of Medicine20